Santhera Pharmaceuticals

Impact: Santhera Pharmaceuticals will receive sales, milestone payments, and royalties from the net sales of AGAMREE in South Korea, Japan, Australia, and New Zealand due to the licensing agreement with Nxera Pharma The Orphan Drug Designation and Global Innovative Products on Fast Track designation for AGAMREE in South Korea are positive developments for the company.

Impact: Santhera expands its distribution network for AGAMREE, potentially increasing revenue and market access in Central Asia and the Caucasus.

Impact: Santhera Pharmaceuticals is the developer of AGAMREE and benefits from positive clinical trial results, which could lead to expanded indications and increased sales-based milestone payments and royalties from its licensing partners.

Impact: Santhera signed a licensing agreement with Nxera for vamorolone in Japan, South Korea, Australia, and New Zealand, expanding access to a Duchenne Muscular Dystrophy treatment.